---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-26-000063"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2026-03-09T23:59:59+00:00"
generated_at: "2026-05-15T17:37:18.156476+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics reports FY2025 net loss of $130.3M; cash $126.9M funds into mid-2027

## Summary
- Net loss of $130.3M ($5.02 per basic share) compared to $77.4M ($4.48) in FY2024.
- R&D expenses rose to $58.0M from $45.1M, driven by Phase 3 AURORA trial and headcount growth.
- Cash, equivalents and restricted cash of $126.9M expected to support operations into mid-2027, including AURORA completion.
- Phase 3 AURORA trial for Descartes-08 in myasthenia gravis on track to enroll ~100 patients; Phase 2 TRITON in myositis IND accepted, initiation expected 1H26.
- Board changes: Adrian Bot appointed in Dec 2025; Carsten Brunn named Chairman in Oct 2025.

## SEC filing metadata
- accession: 0001453687-26-000063
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2026-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000063/0001453687-26-000063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000063/rnac-20260309.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-26-000063
- JSON: https://secwatch.observer/filing/0001453687-26-000063.json
- Plain text: https://secwatch.observer/filing/0001453687-26-000063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.